Loading…

Incidence of community-acquired pneumonia in urban China: A national population-based study

Community-acquired pneumonia (CAP) is one of the major global health problems worldwide. However, the epidemiological information of CAP is limited in China. This study aimed to estimate the incidence rate of CAP and describe the epidemiologic characteristics among the Chinese population. We conduct...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2020-12, Vol.38 (52), p.8362-8370
Main Authors: Sun, Yixin, Li, Hui, Pei, Zhengcun, Wang, Shengfeng, Feng, Jingnan, Xu, Lu, Gao, Pei, Cao, Bin, Zhan, Siyan
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Community-acquired pneumonia (CAP) is one of the major global health problems worldwide. However, the epidemiological information of CAP is limited in China. This study aimed to estimate the incidence rate of CAP and describe the epidemiologic characteristics among the Chinese population. We conducted a retrospective analysis of CAP incidence using the Chinese Urban Basic Medical Insurance database of 23 provinces in 2016, which covered 427.52 million urban beneficiaries of all age groups in Mainland China. CAP episodes were identified using a diagnosis-term-derived algorithm, and multiple CAP records of one single person within 90 continuous days were considered as one single episode. The incidence rates were calculated and described by sex, age, region, and season. A total of 1.42 million patients were identified as having one or more CAP episodes, and finally a sum of 1.48 million CAP episodes were counted. The overall incidence of CAP was 7.13 (95% CI: 6.11–8.15) per 1000 person-years, in males 7.32 (95% CI: 6.28–8.35) and females 6.93 (95% CI: 5.92–7.94) per 1000 person-years, respectively. The incidence varied by age with a U-shaped curve peaking in children aged 
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2020.11.004